# **ModernGraham Valuation**

Vertex Pharmaceuticals Incorporated



#### **Company Name:**

Company Ticker

VRTX

Date of Analysis

8/26/2016

## Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$23,974,743,678 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	2.33 Pass
3. Earnings Stability	Positive EPS for 10 years prior	Fail
4. Dividend Record	Dividend Payments for 10 years prior	Fail
	Increase of 33% in EPS in past 10	
5. Earnings Growth	years using 3 year averages at beginning and end	-45.95% Fail
6. Moderate PEmg Ratio	PEmg < 20	-63.54 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	24.19 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

Current Ratio > 1.5	2.33 Pass
Debt to NCA < 1.1	0.09 Pass
Positive EPS for 5 years prior	Fail
Currently Pays Dividend	Fail
EPSmg greater than 5 years ago	Pass
	Debt to NCA < 1.1 Positive EPS for 5 years prior Currently Pays Dividend

Suitability

Defensive No Enterprising No

#### Stage 2: Determination of Intrinsic Value

EPSmg	-\$1.53
MG Growth Estimate	0.64%
MG Value	\$0.00
MG Value based on 3% Growth	-\$22.16
MG Value based on 0% Growth	-\$12.99
Market Implied Growth Rate	-36.02%

MG Opinion

Current Price \$97.09

% of Intrinsic Value N/A
Opinion Overvalued
MG Grade D

#### Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$0.46
Graham Number	\$1.89
PEmg	-63.54
Current Ratio	2.33
PB Ratio	24.19
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links: ModernGraham tagged articles

 Google Finance
 MSN Money


 Yahoo Finance
 Seeking Alpha

 GuruFocus
 SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$0.04	Next Fiscal Year Estimate	-\$1.53
Dec2015	-\$2.31	Dec2015	-\$2.06
Dec2014	-\$3.14	Dec2014	-\$1.91
Dec2013	-\$1.98	Dec2013	-\$1.52
Dec2012	-\$0.50	Dec2012	-\$1.60
Dec2011	\$0.14	Dec2011	-\$2.34
Dec2010	-\$3.77	Dec2010	-\$3.43
Dec2009	-\$3.71	Dec2009	-\$3.11
Dec2008	-\$3.27	Dec2008	-\$2.71
Dec2007	-\$3.03	Dec2007	-\$2.41
Dec2006	-\$1.83	Dec2006	-\$2.08
Dec2005	-\$2.28	Dec2005	-\$2.09
Dec2004	-\$2.12	Dec2004	-\$1.83
Dec2003	-\$2.56	Dec2003	-\$1.53
Dec2002	-\$1.43	Dec2002	-\$0.97
Dec2001	-\$0.89	Dec2001	-\$0.71
Dec2000	-\$0.51	Dec2000	-\$0.64
Dec1999	-\$0.80	Balance Sheet Information	6/1/2016
Dec1998	-\$0.65	Total Current Assets	\$1,454,150,000
Dec1997	-\$0.41	Total Current Liabilities	\$622,855,000
Dec1996	-\$1.07	Long-Term Debt	\$74,921,000
		Total Assets	\$2,548,982,000
		Intangible Assets	\$334,724,000
		Total Liabilities	\$1,567,628,000
		Shares Outstanding (Diluted Average)	244 482 000

Morningstar





#### Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

### **Recommended Reading:**

Other ModernGraham posts about the company Vertex Pharmaceuticals Analysis – July 2015 Update \$VRTX
Vertex Pharmaceuticals Annual Valuation – 2014 \$VRTX

Other ModernGraham posts about related companies

Amgen Inc Valuation – August 2016 \$AMGN
Pfizer Inc Valuation – August 2016 \$PFE

Abbott Laboratories Valuation – August 2016 \$ABT Johnson & Johnson Valuation – August 2016 \$JNJ

Regeneron Pharmaceuticals Inc Valuation – August 2016 \$REGN

AmerisourceBergen Corp Valuation – July 2016 \$ABC

Perrigo Co PLC Valuation – July 2016 \$PRGO

AbbVie Inc Valuation – July 2016 \$ABBV

Gilead Sciences Inc Valuation - July 2016 \$GILD

Eli Lilly and Company Valuation - July 2016 \$LLY